Trinity Biotech plc is a diagnostics & research business based in the US. Trinity Biotech shares (TRIB) are listed on the NASDAQ and all prices are listed in US Dollars. Trinity Biotech employs 543 staff and has a trailing 12-month revenue of around 0.00.
How to buy shares in Trinity Biotech
- Compare share trading platforms.Use our comparison table to help you find a platform that fits you.
- Open your brokerage account. Complete an application with your details.
- Confirm your payment details. Fund your account.
- Research the stock. Find the stock by name or ticker symbol – TRIB – and research it before deciding if it's a good investment for you.
- Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
- Check in on your investment. Optimize your portfolio by tracking your stock.
What's in this guide?
- TRIB shares summary
- Compare share dealing platforms
- Is TRIB stock a buy or sell?
- Stock performance over time
- Can I short TRIB shares?
- Are TRIB shares over-valued?
- Trinity Biotech's financials
- How volatile are TRIB shares?
- Does Trinity Biotech pay a dividend?
- Have TRIB shares ever split?
- Other common questions
Trinity Biotech stock price (NASDAQ: TRIB)Use our graph to track the performance of TRIB stocks over time.
Trinity Biotech shares at a glance
|Latest market close||$2.06|
|52-week range||$1.75 - $6.82|
|50-day moving average||$2.32|
|200-day moving average||$2.78|
|Wall St. target price||$7.00|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||$-0.09|
Buy Trinity Biotech shares from these brokeragesCompare special offers, low fees and a wide range of types of investments among top trading platforms.
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
Is it a good time to buy Trinity Biotech stock?
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Trinity Biotech price performance over time
|1 week (2021-10-13)||-6.36%|
|1 month (2021-09-21)||-9.25%|
|3 months (2021-07-21)||5.64%|
|6 months (2021-04-21)||-42.30%|
|1 year (2020-10-20)||-21.67%|
|2 years (2019-10-18)||157.69%|
|3 years (2018-10-19)||3.41|
|5 years (2016-10-20)||7.07|
Is Trinity Biotech under- or over-valued?
Valuing Trinity Biotech stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Trinity Biotech's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Trinity Biotech's PEG ratio
Trinity Biotech's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 1.3. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.
The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into Trinity Biotech's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.
Trinity Biotech's EBITDA
Trinity Biotech's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $27.7 million.
The EBITDA is a measure of a Trinity Biotech's overall financial performance and is widely used to measure a its profitability.
Trinity Biotech financials
|Revenue TTM||$116.2 million|
|Operating margin TTM||22.04%|
|Gross profit TTM||$48.6 million|
|Return on assets TTM||12.63%|
|Return on equity TTM||-683%|
|Market capitalisation||$42.4 million|
TTM: trailing 12 months
Shorting Trinity Biotech shares
There are currently 279,283 Trinity Biotech shares held short by investors – that's known as Trinity Biotech's "short interest". This figure is 0% up from 279,169 last month.
There are a few different ways that this level of interest in shorting Trinity Biotech shares can be evaluated.
Trinity Biotech's "short interest ratio" (SIR)
Trinity Biotech's "short interest ratio" (SIR) is the quantity of Trinity Biotech shares currently shorted divided by the average quantity of Trinity Biotech shares traded daily (recently around 133628.22966507). Trinity Biotech's SIR currently stands at 2.09. In other words for every 100,000 Trinity Biotech shares traded daily on the market, roughly 2090 shares are currently held short.
However Trinity Biotech's short interest can also be evaluated against the total number of Trinity Biotech shares, or, against the total number of tradable Trinity Biotech shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Trinity Biotech's short interest could be expressed as 0.01% of the outstanding shares (for every 100,000 Trinity Biotech shares in existence, roughly 10 shares are currently held short) or 0.018% of the tradable shares (for every 100,000 tradable Trinity Biotech shares, roughly 18 shares are currently held short).
Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Trinity Biotech.
Find out more about how you can short Trinity Biotech stock.
Trinity Biotech share dividends
We're not expecting Trinity Biotech to pay a dividend over the next 12 months.
Have Trinity Biotech's shares ever split?
Trinity Biotech's shares were split on a 1:4 basis on 1 June 2005. So if you had owned 4 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Trinity Biotech shares – just the quantity. However, indirectly, the new 300% higher share price could have impacted the market appetite for Trinity Biotech shares which in turn could have impacted Trinity Biotech's share price.
Trinity Biotech share price volatility
Over the last 12 months, Trinity Biotech's shares have ranged in value from as little as $1.75 up to $6.82. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Trinity Biotech's is 1.6931. This would suggest that Trinity Biotech's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).
Trinity Biotech overview
Trinity Biotech plc acquires, develops, manufactures, and markets medical diagnostic products for the clinical laboratory and point-of-care (POC) segments of the diagnostic market in the United States, Africa, Asia, and Europe. The company offers clinical laboratory products, including diagnostic tests and instrumentation, which detect infectious diseases, such as lyme disease; sexually transmitted diseases consisting syphilis and herpes; SARS-CoV-2; and epstein barr, measles, mumps, toxoplasmosis, cytomegalovirus, rubella, varicella and other viral pathogens, as well as products for the in-vitro diagnostic testing for haemoglobin A1c used in the monitoring and diagnosis of diabetes, and identifying those who are at a risk of developing diabetes. It also develops, manufactures, and distributes products in the immunofluorescence assay, enzyme-linked immunosorbent, western blot, and line immunoassay formats; and provides reagent products, such as ACE, bile acids, lactate, oxalate, and glucose-6-phosphate dehydrogenase for diagnosis of liver and kidney diseases, as well as haemolytic anaemia. In addition, the company sells raw materials to the life sciences industry and research institutes. The company sells its products through its direct sales force; and a network of independent distributors and strategic partners. Its customers include public health facilities, hospitals, and other outreach facilities, as well as clinical and reference laboratories. Trinity Biotech plc was incorporated in 1992 and is headquartered in Bray, Ireland.
Trinity Biotech in the news
Trinity Biotech : Announces Results of AGM (Form 6-K)
Sidoti - Fall Virtual Small Cap Investor Conference
Frequently asked questionsWhat percentage of Trinity Biotech is owned by insiders or institutions?
Currently 15.148% of Trinity Biotech shares are held by insiders and 40.903% by institutions. How many people work for Trinity Biotech?
Latest data suggests 543 work at Trinity Biotech. When does the fiscal year end for Trinity Biotech?
Trinity Biotech's fiscal year ends in December. Where is Trinity Biotech based?
Trinity Biotech's address is: IDA Business Park, Bray, Ireland What is Trinity Biotech's ISIN number?
Trinity Biotech's international securities identification number is: US8964383066 What is Trinity Biotech's CUSIP number?
Trinity Biotech's Committee on Uniform Securities Identification Procedures number is: 896438108
More guides on Finder
How to buy ProShares Bitcoin Strategy ETF (BITO)
Steps to owning and managing ProShares Bitcoin Strategy ETF units.
How to buy The Real Good Food Company (RGF) stock when it goes public
Everything we know about the The Real Good Food Company IPO, plus information on how to buy in.
How to buy Lulu’s Fashion Lounge Holdings (LVLU) stock when it goes public
Everything we know about the Lulu’s Fashion Lounge Holdings IPO, plus information on how to buy in.
How to buy Allarity Therapeutics (ALLR) stock when it goes public
Everything we know about the Allarity Therapeutics IPO, plus information on how to buy in.
How to buy Jupiter Neurosciences (JUNS) stock when it goes public
Everything we know about the Jupiter Neurosciences IPO, plus information on how to buy in.
How to buy Mainz Biomed (MYNZ) stock when it goes public
Everything we know about the Mainz Biomed IPO, plus information on how to buy in.
How to buy Progressive Care stock when it goes public
Everything we know about the Progressive Care IPO, plus information on how to buy in.
How to buy Desert Peak Minerals (DPM) stock when it goes public
Everything we know about the Desert Peak Minerals IPO, plus information on how to buy in.
How to buy Vaxxinity (VAXX) stock when it goes public
Everything we know about the Vaxxinity IPO, plus information on how to buy in.
How to buy Entrada Therapeutics (TRDA) stock when it goes public
Everything we know about the Entrada Therapeutics IPO, plus information on how to buy in.
Ask an Expert